{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05548452",
            "orgStudyIdInfo": {
                "id": "HM20025442"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01AA029398",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01AA029398"
                }
            ],
            "organization": {
                "fullName": "Virginia Commonwealth University",
                "class": "OTHER"
            },
            "briefTitle": "Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease",
            "officialTitle": "Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial",
            "acronym": "IMPACT",
            "therapeuticArea": [
                "Hepatology",
                "Other",
                "Gastroenterology"
            ],
            "study": "intestinal-microbiota-transplant-in-alcohol-associated-liver-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-16",
            "studyFirstSubmitQcDate": "2022-09-16",
            "studyFirstPostDateStruct": {
                "date": "2022-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Virginia Commonwealth University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.",
            "detailedDescription": "These intestinal microbiota transplant (IMT) capsules are an investigational drug, which means it has not been approved by the U. S. Food and Drug Administration (FDA). In this study, drug name will be compared to placebo (a look-alike inactive substance, a \"sugar pill\").\n\nParticipants will be randomly assigned (like the flip of a coin) to receive either IMT capsules or placebo capsules. Participants have an equal chance of being assigned to any one of the groups.\n\nIn this study, participants will be asked to do the following things:\n\n1. Visit VCU medical center up to 8 times for study visits\n2. Take either IMT capsule or the placebo, depending upon which group they are assigned to; these capsules will be given twice on enrollment and after one month\n3. Have blood drawn, urine and stool collected at each visit\n4. Have testing done to determine the speed of brain function\n5. Keep a diary at home\n6. Take surveys and answer questions about general health, alcohol craving and consumption and how they are feeling.\n7. Give permission for the researchers to collect information about liver disease, alcohol and mental health from medical records.\n\nParticipation in this study will last up to 7 months."
        },
        "conditionsModule": {
            "conditions": [
                "Liver Disease; Alcohol-Related",
                "Cirrhosis",
                "Alcohol Use Disorder"
            ],
            "keywords": [
                "Intestinal Microbiota Transplant",
                "Alcohol Use Disorder",
                "Cirrhosis",
                "Chronic Liver Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intestinal Microbiota Transplant capsules",
                    "type": "EXPERIMENTAL",
                    "description": "Capsules will be provided twice during the trial",
                    "interventionNames": [
                        "Drug: Intestinal Microbiota Transplant (IMT) Capsules"
                    ]
                },
                {
                    "label": "Placebo capsules",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Capsules will be provided twice during the trial",
                    "interventionNames": [
                        "Drug: Placebo Capsules"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Intestinal Microbiota Transplant (IMT) Capsules",
                    "description": "Capsules containing freeze-dried intestinal microbiota from healthy human donors",
                    "armGroupLabels": [
                        "Intestinal Microbiota Transplant capsules"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo Capsules",
                    "description": "Capsules containing an inactive substance (\"sugar pill\")",
                    "armGroupLabels": [
                        "Placebo capsules"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Alcohol consumption",
                    "description": "Number of drinks per day will be measured through self report",
                    "timeFrame": "Baseline to 3 months after treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in markers of alcohol in urine",
                    "description": "Urine samples will be analyzed for levels of Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS)",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in markers of alcohol in blood",
                    "description": "Blood samples will be analyzed for Phosphatidyl Ethanol (PEth)",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in percentage of heavy drinking days",
                    "description": "Self reported drinking behavior will be used to calculate percentage of heavy drinking days",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in alcohol craving",
                    "description": "The Alcohol Craving Questionnaire is a 12-item instrument",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in life problems",
                    "description": "The Short Index of Problems is a 15-item instrument which measures medical, psychological, social, occupational, and legal problems.",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Number of hospitalizations",
                    "description": "All hospitalizations and liver-related hospitalizations will be tracked",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Number of serious adverse events",
                    "description": "All serious adverse events and intervention related adverse events will be tracked",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Change in microbial composition",
                    "description": "Percentage of beneficial intestinal bacteria will be assessed by genetic analysis of stool samples.",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in liver function",
                    "description": "The Model for end-stage liver disease (MELD) score will be used to asses changes in liver function.",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in Psychometric hepatic encephalopathy score (PHES)",
                    "description": "Brain function will be assessed using the PHES",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in EncephalApp Stroop Test",
                    "description": "Brain function will be assessed using the EncephalApp Stroop Test",
                    "timeFrame": "Baseline to 3 months after treatment"
                },
                {
                    "measure": "Change in health related quality of live (HRQOL)",
                    "description": "HRQOL will be assessed using the Sickness Impact Profile",
                    "timeFrame": "Baseline to 3 months after treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n-\\>18 years of age\n\n* Advanced liver disease\n* Able to give written, informed consent\n* Alcohol as a cause of advanced liver disease\n* Continued sustained drinking\n* Having previously declined a referral to traditional AUD therapy services or having failed such treatments\n\nExclusion Criteria:\n\n* Lack of sustained drinking\n* Recent or current alcoholic hepatitis\n* Alcohol withdrawal symptoms\n* Clinically significant use of illicit drugs\n* Uncontrolled mood disorders or primary psychotic conditions\n* MELD score\\>17\n* Unclear diagnosis of chronic liver disease\n* Current hepatic encephalopathy on lactulose and/or rifaximin\n* WBC count\\<1000\n* Non-elective hospitalization within last month\n* on dialysis\n* known untreated, in-situ luminal GI cancers\n* chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease)\n* Dysphagia within 2 weeks\n* History of aspiration, gastroparesis, intestinal obstruction\n* Ongoing absorbable antibiotic use\n* Severe anaphylactic food allergy\n* allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil)\n* Adverse event attributable to prior IMT\n* ASA Class IV or V\n* Pregnant or nursing patients\n* acute illness or fever on the day of planned FMT\n* Immunosuppression\n* Other conditions which make patients are poor candidate for this study per investigator judgement",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jasmohan S Bajaj, MD",
                    "role": "CONTACT",
                    "phone": "804 675 5802",
                    "email": "jasmohan.bajaj@vcuhealth.org"
                },
                {
                    "name": "Amy Bartels, BSN, RN",
                    "role": "CONTACT",
                    "phone": "804-828-3849",
                    "email": "Amy.Bartels1@vcuhealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jasmohan S Bajaj, MD",
                    "affiliation": "Virginia Commonwealth University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Hunter Holmes McGuire VA Medical Center",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23249",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Virginia Commonwealth University",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Deidentified data via NIAAA DA website",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                },
                {
                    "id": "D000000437",
                    "term": "Alcoholism"
                },
                {
                    "id": "D000000428",
                    "term": "Alcohol Drinking"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000004327",
                    "term": "Drinking Behavior"
                },
                {
                    "id": "D000019973",
                    "term": "Alcohol-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3774",
                    "name": "Alcohol Drinking",
                    "asFound": "Alcohol Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3783",
                    "name": "Alcoholism",
                    "asFound": "Alcohol Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7502",
                    "name": "Drinking Behavior",
                    "relevance": "LOW"
                },
                {
                    "id": "M21842",
                    "name": "Alcohol-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M3777",
                    "name": "Ethanol",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}